Therefore, in the attempt to identify the contribution of PNPLA3 variant to PLT count, we stratified 1155 biopsy-proven MASLD patients according to the PNPLA3 rs738409 (p.I148M, C>G) variant (n = 484 CC (41.9%), n = 485 CG (42%) and n = 186 GG (16.1%)) (Table 1 and Table S1). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.